EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aclaris Therapeutics's enterprise value is $17.75 Mil.
Aclaris Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-53.49 Mil. Therefore, Aclaris Therapeutics's EV-to-EBITDA for today is -0.33.
The historical rank and industry rank for Aclaris Therapeutics's EV-to-EBITDA or its related term are showing as below:
ACRS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.54 Med: -3.22 Max: 0.71
Current: -0.33
During the past 12 years, the highest EV-to-EBITDA of Aclaris Therapeutics was 0.71. The lowest was -29.54. And the median was -3.22.
ACRS's EV-to-EBITDA is ranked worse than 100% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs ACRS: -0.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Aclaris Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Aclaris Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aclaris Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Aclaris Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's EV-to-EBITDA falls into.
Aclaris Therapeutics's current Enterprise Value is $17.75 Mil.
Aclaris Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aclaris Therapeutics's PE Ratio (TTM) for today is calculated as:
Aclaris Therapeutics's share price for today is $1.26.
Aclaris Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Aclaris Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACRS has been successfully added to your 